title: Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients.
authors.affiliation: Abteilung Nephrologie Zentrum Innere Medizin, Medizinische Hochschule Hannover, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Kliem
authors.forename: D
authors.initials: D
authors.lastname: Schaumann
authors.forename: G
authors.initials: G
authors.lastname: Ehlerding
authors.forename: O K
authors.initials: OK
authors.lastname: Eberhard
authors.forename: V
authors.initials: V
authors.lastname: Lufft
authors.forename: H J
authors.initials: HJ
authors.lastname: Schlitt
authors.forename: R
authors.initials: R
authors.lastname: Pichlmayr
authors.forename: K M
authors.initials: KM
authors.lastname: Koch
authors.forename: R
authors.initials: R
authors.lastname: Brunkhorst
mesh_terms: D000328:Adult; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus